SETP9

Across TCGA pan-cancer cohorts, SETP9 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SETP9’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SETP9 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SETP9 is over-expressed in tumor, although a few such as LUSC and COAD show the opposite, repressed pattern.

KIRC, LUSC, and COAD are the cancer types where SETP9 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SETP9 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	+0.074	<.001	10	view →
LUSC	Female	II,III,IV	−0.187	<.001	4	view →
COAD	All	III,IV	−0.097	.019	3	view →
STAD	All	All	+0.084	.013	2	view →
LIHC	All	II,III,IV	+0.030	.035	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SETP9–KIRC

Open the KIRC breakdown →